{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T12:54:59Z","timestamp":1754484899734},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cardiothorac Surg"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Coronary artery bypass grafting (CABG) is associated with antithrombotic therapy in terms of postoperative adverse events; however, it is still unknown whether the early use of such drugs after CABG is safe and effective. In this study, we aim to evaluate the relationship between different postoperative antithrombotic strategies and in-hospital adverse events in patients undergoing isolated coronary artery bypass grafting surgery.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a single-center, retrospective cohort analysis of patients undergoing isolated CABG due to coronary artery disease (CAD) between 2001 and 2012. Data were extracted from the Medical Information Mart for Intensive Care III database. The patients involved were divided into the ASA (aspirin 81\u00a0mg per day only) or DAPT (aspirin plus clopidogrel 75\u00a0mg per day) group according to the antiplatelet strategy. Patients were also stratified into subgroups based on the type of anticoagulation. The in-hospital risk of bleeding and adverse events was investigated and compared between groups. Propensity score matching (PSM) was performed to reduce the potential effects of a selection bias.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 3274 patients were included in this study, with 2358 in the ASA group and 889 in the DAPT group. Following the PSM, no significant difference was seen in the risk of major bleeding between the two groups according to the PLATO, TIMI or GUSTO criteria. There was no difference in the postoperative mortality. In subgroup analysis, patients given anticoagulant therapy had an increased incidence of bleeding-related events. Multivariable analysis revealed that postoperative anticoagulant therapy and the early use of heparin, but not DAPT, were independent predictors of bleeding-related events.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Postoperative DAPT was not associated with an increased occurrence of bleeding-related events in patients undergoing isolated CABG and appears to be a safe antiplatelet therapy. The addition of anticoagulants to antiplatelet therapy increased the risk of bleeding and should be considered cautiously in clinical practice.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13019-024-02937-y","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T07:02:16Z","timestamp":1720076536000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Different antithrombotic strategies after coronary artery bypass grafting to prevent adverse events: a retrospective analysis"],"prefix":"10.1186","volume":"19","author":[{"given":"Yi","family":"Shi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenglong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Lian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,4]]},"reference":[{"issue":"2","key":"2937_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","volume":"40","author":"FJ Neumann","year":"2019","unstructured":"Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC\/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87\u2013165.","journal-title":"Eur Heart J"},{"issue":"3","key":"2937_CR2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"M Valgimigli","year":"2018","unstructured":"Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213\u201360.","journal-title":"Eur Heart J"},{"issue":"24","key":"2937_CR3","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1093\/eurheartj\/ehs367","volume":"33","author":"V Farooq","year":"2012","unstructured":"Farooq V, Serruys PW, Bourantas C, et al. Incidence and multivariable correlates of long-term mortality in patients treated with surgical or percutaneous revascularization in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial. Eur Heart J. 2012;33(24):3105\u201313.","journal-title":"Eur Heart J"},{"issue":"2","key":"2937_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1056\/NEJM198207083070201","volume":"307","author":"JH Chesebro","year":"1982","unstructured":"Chesebro JH, Clements IP, Fuster V, et al. A platelet-inhibitor-drug trial in coronary-artery bypass operations: benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency. N Engl J Med. 1982;307(2):73\u20138.","journal-title":"N Engl J Med"},{"issue":"3","key":"2937_CR5","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/0002-8703(92)90496-I","volume":"123","author":"WD Johnson","year":"1992","unstructured":"Johnson WD, Kayser KL, Hartz AJ, Saedi SF. Aspirin use and survival after coronary bypass surgery. Am Heart J. 1992;123(3):603\u20138.","journal-title":"Am Heart J"},{"issue":"3","key":"2937_CR6","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s11239-011-0613-6","volume":"32","author":"JC Sun","year":"2011","unstructured":"Sun JC, Teoh KH, Sheth T, et al. Randomized trial of fondaparinux versus heparin to prevent graft failure after coronary artery bypass grafting: the Fonda CABG study. J Thromb Thrombolysis. 2011;32(3):378\u201385.","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"2937_CR7","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jacc.2010.10.029","volume":"57","author":"C Held","year":"2011","unstructured":"Held C, Asenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (platelet inhibition and patient outcomes) trial. J Am Coll Cardiol. 2011;57(6):672\u201384.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2937_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0735-1097(88)90158-1","volume":"11","author":"AK Rao","year":"1988","unstructured":"Rao AK, Pratt C, Berke A, et al. Thrombolysis in myocardial infarction (TIMI) trial\u2013phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988;11(1):1\u201311.","journal-title":"J Am Coll Cardiol"},{"issue":"9272","key":"2937_CR9","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(00)05060-1","volume":"357","author":"ML Simoons","year":"2001","unstructured":"Simoons ML, GUSTO IV-ACS investigators. Effect of glycoprotein IIb\/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet. 2001;357(9272):1915\u201324.","journal-title":"Lancet"},{"issue":"18","key":"2937_CR10","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.jacc.2018.08.1038","volume":"72","author":"K Thygesen","year":"2018","unstructured":"Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol. 2018;72(18):2231\u201364.","journal-title":"J Am Coll Cardiol"},{"key":"2937_CR11","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation. 2011;123:2736\u201347.","journal-title":"Circulation"},{"issue":"4","key":"2937_CR12","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/j.athoracsur.2005.01.008","volume":"79","author":"VA Ferraris","year":"2005","unstructured":"Ferraris VA, Ferraris SP, Moliterno DJ, et al. The society of thoracic surgeons practice guideline series: aspirin and other antiplatelet agents during operative coronary revascularization (executive summary). Ann Thorac Surg. 2005;79(4):1454\u201361.","journal-title":"Ann Thorac Surg"},{"issue":"4","key":"2937_CR13","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/1010-7940(93)90155-5","volume":"7","author":"SE Fremes","year":"1993","unstructured":"Fremes SE, Levinton C, Naylor CD, Chen E, Christakis GT, Goldman BS. Optimal antithrombotic therapy following aortocoronary bypass: a meta-analysis. Eur J Cardiothorac Surg. 1993;7(4):169\u201380.","journal-title":"Eur J Cardiothorac Surg"},{"issue":"1","key":"2937_CR14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ejcts.2008.02.024","volume":"34","author":"J Dunning","year":"2008","unstructured":"Dunning J, Versteegh M, Fabbri A, et al. Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur J Cardiothorac Surg. 2008;34(1):73\u201392.","journal-title":"Eur J Cardiothorac Surg"},{"issue":"10","key":"2937_CR15","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1161\/01.CIR.0000140675.85342.1B","volume":"110","author":"KA Fox","year":"2004","unstructured":"Fox KA, Mehta SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the clopidogrel in unstable angina to prevent recurrent ischemic events (CURE) trial. Circulation. 2004;110(10):1202\u20138.","journal-title":"Circulation"},{"issue":"5","key":"2937_CR16","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jacc.2012.03.030","volume":"60","author":"PK Smith","year":"2012","unstructured":"Smith PK, Goodnough LT, Levy JH, et al. Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. J Am Coll Cardiol. 2012;60(5):388\u201396.","journal-title":"J Am Coll Cardiol"},{"key":"2937_CR17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ijcard.2018.07.083","volume":"269","author":"R Cardoso","year":"2018","unstructured":"Cardoso R, Knijik L, Whelton SP, et al. Dual versus single antiplatelet therapy after coronary artery bypass graft surgery: an updated meta-analysis. Int J Cardiol. 2018;269:80\u20138.","journal-title":"Int J Cardiol"},{"issue":"2","key":"2937_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/jocs.12074","volume":"28","author":"SV Deo","year":"2013","unstructured":"Deo SV, Dunlay SM, Shah IK, et al. Dual anti-platelet therapy after coronary artery bypass grafting: is there any benefit? A systematic review and meta-analysis. J Card Surg. 2013;28(2):109\u201316.","journal-title":"J Card Surg"},{"issue":"10","key":"2937_CR19","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1161\/CIR.0000000000000404","volume":"134","author":"GN Levine","year":"2016","unstructured":"Levine GN, Bates ER, Bittl JA, et al. 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice guidelines: an update of the 2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention, 2011 ACCF\/AHA Guideline for coronary artery bypass graft surgery, 2012 ACC\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS Guideline for the diagnosis and management of patients with stable ischemic heart Disease, 2013 ACCF\/AHA Guideline for the management of ST-Elevation myocardial infarction, 2014 AHA\/ACC Guideline for the management of patients with Non-ST-Elevation Acute Coronary syndromes, and 2014 ACC\/AHA Guideline on Perioperative Cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2016;134(10):e123\u201355.","journal-title":"Circulation"},{"issue":"03","key":"2937_CR20","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1160\/TH16-09-0721","volume":"117","author":"F Biancari","year":"2017","unstructured":"Biancari F, Brascia D, Onorati F, et al. Prediction of severe bleeding after coronary surgery: the WILL-BLEED risk score. Thromb Haemost. 2017;117(03):445\u201356.","journal-title":"Thromb Haemost"},{"issue":"9706","key":"2937_CR21","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1016\/S0140-6736(09)61751-7","volume":"374","author":"R sorensen","year":"2009","unstructured":"sorensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009;374(9706):1967\u201374.","journal-title":"Lancet"},{"issue":"5","key":"2937_CR22","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","volume":"127","author":"AL Dans","year":"2013","unstructured":"Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation. 2013;127(5):634\u201340.","journal-title":"Circulation"}],"container-title":["Journal of Cardiothoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13019-024-02937-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13019-024-02937-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13019-024-02937-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T07:06:18Z","timestamp":1720076778000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiothoracicsurgery.biomedcentral.com\/articles\/10.1186\/s13019-024-02937-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,4]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2937"],"URL":"https:\/\/doi.org\/10.1186\/s13019-024-02937-y","relation":{},"ISSN":["1749-8090"],"issn-type":[{"value":"1749-8090","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,4]]},"assertion":[{"value":"23 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The establishment of this database was approved by the Massachusetts Institute of Technology (Cambridge, MA) and Beth Israel Deaconess Medical Center (Boston, MA) and consent was obtained for the original data collection. Therefore, the ethical approval statement and the need for informed consent were waived for this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"422"}}